概括
儿童癌症患者可以在伦理上接受非标签的甲福明,以预防复发. 仔细考虑其安全概况和新兴研究支持这种方法在特定情况下.
科学领域:
- 儿科瘤学 儿科瘤学
- 医学伦理 医学伦理
- 药理学 药理学是指药理学的学科.
背景情况:
- 儿科瘤学经常遇到关于未经证实的治疗方法的伦理困境.
- 家庭可能会要求为罕见的儿科癌症提供新的治疗方法,这给临床医生带来了挑战.
研究的目的:
- 分析为儿童癌症患者开处方未经证实的疗法 - - 甲福明的伦理考虑.
- 讨论儿童瘤学中基于证据的医学和以患者为中心的护理之间的平衡.
主要方法:
- 对一个处于缓解期的三岁儿科癌症患者的案例研究分析.
- 审查临床证据,安全概况和对甲福明的监管批准.
- 在儿科瘤学中适用于非标签处方的伦理框架.
主要成果:
- 梅特福林的良好的安全性概况和现有的儿科食品和药物管理局批准支持其考虑.
- 新兴的癌症研究和专家的认可要求仔细评估非标签使用.
- 由于罕见疾病和临床试验的局限性,非标签处方在儿科瘤学中很普遍.
结论:
- 为预防儿科癌症复发而非标签处方甲福明可能在知情同意和监测下在伦理上是合理的.
- 在儿童癌症治疗决策中,平衡基于证据的实践与以家庭为中心的护理至关重要.
- 在复杂的儿科瘤病例中,跨学科的投入对于在道德上健全的患者护理至关重要.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
830
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
830
Pharmacokinetics in Pediatric Patients: Drug Metabolism
313
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
313
Pharmacokinetics in Pediatric Patients: Drug Excretion
360
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
360
Hypoglycemia and Glucagon
1.2K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.2K
Antiepileptic Drugs: Potassium Channel Activators
902
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
902
Drug Dosing: Infants and Children
692
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
692


